Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia (2019)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1007/s10557-019-06852-6
- Subjects: HIPERCOLESTEROLEMIA; ERROS INATOS DO METABOLISMO; ENZIMAS PROTEOLÍTICAS; FATORES DE RISCO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Cardiovascular drugs and therapy
- ISSN: 0920-3206
- Volume/Número/Paginação/Ano: v. 33, n. 1, p. 69-76, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
GINSBERG, Henry N et al. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular drugs and therapy, v. 33, n. 1, p. 69-76, 2019Tradução . . Disponível em: https://doi.org/10.1007/s10557-019-06852-6. Acesso em: 27 jan. 2026. -
APA
Ginsberg, H. N., Tuomilehto, J., Hovingh, G. K., Cariou, B., Santos Filho, R. D. dos, Brown, A. S., et al. (2019). Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular drugs and therapy, 33( 1), 69-76. doi:10.1007/s10557-019-06852-6 -
NLM
Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos Filho RD dos, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia [Internet]. Cardiovascular drugs and therapy. 2019 ; 33( 1): 69-76.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1007/s10557-019-06852-6 -
Vancouver
Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos Filho RD dos, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia [Internet]. Cardiovascular drugs and therapy. 2019 ; 33( 1): 69-76.[citado 2026 jan. 27 ] Available from: https://doi.org/10.1007/s10557-019-06852-6 - Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study
- Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia
- Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study
- Vertebral bone density by quantitative computed tomography mirrors bone structure histomorphometric parameters in hemodialysis patients
- Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia
- Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype [Editorial]: What do genetic defects tell us and what are the clinical implications?
- Sodium intake and prevalence of hypertension in elementary school students
- Clinical Genetic Testing for Familial Hypercholesterolemia
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab
Informações sobre o DOI: 10.1007/s10557-019-06852-6 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
